Company Description
COSCIENS Biopharma Inc., a life science company, engages in developing and commercializing products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Columbia, the United Kingdom, and internationally.
The company lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications.
It has a license agreement with NK MEDITECH Ltd. and Er-Kim Pharmaceuticals Bulgaria Eood for the development and commercialization of macimorelin.
The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.
COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
| Country | Canada |
| Founded | 1990 |
| IPO Date | Jul 18, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Anna Biehn |
Contact Details
Address: 222 Bay Street, Suite 3000 Toronto, ON M5K 1E7 Canada | |
| Website | cosciensbio.com |
Stock Details
| Ticker Symbol | CSCI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001113423 |
| CUSIP Number | 22112H101 |
| ISIN Number | CA22112H1010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anna Elizabeth Biehn | Chief Executive Officer |
| Giuliano La Fratta | Senior Vice President of Finance and Chief Financial Officer |
| Michel Regnier P. Eng. | Senior Vice President of Technical operations, MD of Ceapro Inc. and Chief Technology Officer |
| Dr. Michael Teifel Ph.D. | Senior Vice President of GmbH and Chief Scientific Officer |
| Dr. Matthias Gerlach | Senior Vice President Manufacturing and Supply Chain and Head of Production |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2025 | 6-K | Report of foreign issuer |
| May 27, 2025 | 6-K | Report of foreign issuer |
| May 20, 2025 | 6-K | Report of foreign issuer |
| May 13, 2025 | 6-K | Report of foreign issuer |
| May 13, 2025 | 6-K | Report of foreign issuer |
| May 2, 2025 | 6-K | Report of foreign issuer |
| Apr 14, 2025 | 6-K | Report of foreign issuer |
| Apr 9, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 9, 2025 | 6-K | Report of foreign issuer |
| Apr 2, 2025 | 6-K | Report of foreign issuer |